Breaks Categories: Stock Spotlights

FridayJan 20, 2017 12:31 pm

NetworkNewsBreaks – The Singing Machine Company, Inc. (SMDM) Sees Growing Demand Abroad, Forecasts 100% Increase in International Sales

The Singing Machine Company (OTCQX: SMDM) distributes a full line of increasingly popular consumer-oriented karaoke systems and products that have been featured on Mashable, The Wall Street Journal, Wired, USA Today, and other high-profile publications. The company recently posted its 10th consecutive quarter of YoY growth in sales and earnings, the most recent of which was driven by organic and international growth, new products, and buying trends leading up to the holidays. Second-quarter earnings increased 66% to $0.05 per share on net sales of $28.1 million, an increase of 33% compared to the year ago quarter. Noting strong product demand overseas,…

Continue Reading

FridayJan 20, 2017 12:29 pm

NetworkNewsBreaks – MagneGas Corporation (NASDAQ: MNGA) Creates New Revenue Streams in Florida’s Leisure Markets with Commercial Sale of CO2

MagneGas (NASDAQ: MNGA) is a technology company engaged in the renewable resources and environmental solutions industries. The company is known primarily for its patented process that converts various renewables and liquid wastes into MagneGas fuels for use as an alternative to natural gas or for metal cutting. MagneGas recently announced the expansion of its product offering to include the commercial sale of carbon dioxide (CO2), which is primarily used in the food, oil and chemical industries. Recognizing CO2 as a complimentary product offering to its current industrial gas segment and retail infrastructure, the company anticipates that the sale of CO2…

Continue Reading

FridayJan 20, 2017 12:27 pm

NetworkNewsBreaks – Ballard Power Systems (NASDAQ: BLDP) Geared to Fight China’s Smog Problem

China’s hazardous levels of air pollution have officials in various cities calling for temporary closures in highways, flights and industrial plants. Meanwhile, Ballard Power Systems (NASDAQ: BLDP) is working with Guangdong Nation Synergy Hydrogen Power Technology Co. Ltd to establish fuel cell stack production in the City of Yunfu in the Guangdong Province. Under an agreement reached in October 2016, Ballard will receive $170 million over five years for a working deal that includes the creation of a joint venture who will manufacture and sell FCvelocity®-9SSL stacks to be used primarily in locally-assembled fuel cell engines to provide propulsion power…

Continue Reading

FridayJan 20, 2017 12:23 pm

NetworkNewsBreaks – The Alkaline Water Company Inc. (WTER) Continues Rapid Expansion; Lands 2 More Retail Grocery Chains

The Alkaline Water Company (OTCQB: WTER), developer of the innovative bottled alkaline drinking water Alkaline88, recently announced it will shelve its products in two additional retail grocery chains: Fresh Thyme Farmers Markets and Food Depot. Alkaline88 is now available in more than 20,000 stores throughout the United States. The company is consistently adding news stores to its roster, and in early November said more than 1,800 additional stores in the Southeast are now carrying the Alkaline88 brand – which is expected to increase fiscal 2018 revenue by at least 8%. To learn more visit www.thealkalinewaterco.com About The Alkaline Water Company…

Continue Reading

ThursdayJan 19, 2017 12:26 pm

NetworkNewsBreaks – Celsius Holdings, Inc. (CELH) Sees Strength in International Presence, Sales

Celsius Holdings (OTCQX: CELH) is science-based beverage company actively expanding its international presence. The company most recently launched its CELSIUS® fitness drink into supermarkets, convenience and specialty stores and fitness centers in Singapore.  News of this expansion followed a record third-quarter performance, marked by sales of $6.7 million, up 82% YoY. While domestic revenue grew 53%, the company saw particular strength in international sales, which increased 147%. Celsius in November also partnered with the A.S. Watson Group (ASW) for distribution of CELSIUS in Hong Kong and Macau, providing a foothold in the growing Chinese energy drink category. To learn more…

Continue Reading

ThursdayJan 19, 2017 11:56 am

NetworkNewsBreaks – CV Sciences, Inc. (CVSI) Mines the Benefits of Science and Nature to Build Cannabidiol-Based Portfolio

The strategic integration of science and nature is the cornerstone of operations at CV Sciences (OTCQB: CVSI). Its Pharmaceuticals Division, for example, is developing synthetically formulated cannabidiol (CBD)‐based medicine for which the company is pursuing FDA approval. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for the treatment of a range of medical conditions. The company’s initial drug candidate (CVSI-007) is a chewing gum containing nicotine and synthetic CBD to support cessation of smokeless tobacco use and addiction. Focusing on enhancing the quality of life, CV Sciences’ Consumer Products Division delivers botanical-based CBD products such…

Continue Reading

ThursdayJan 19, 2017 11:48 am

NetworkNewsBreaks – Rosetta Genomics Ltd. (NASDAQ: ROSG) Sets Stage for Value Creation in 2017

Rosetta Genomics (NASDAQ: ROSG) is an international company leveraging a growing IP portfolio to develop and commercialize microRNA-based and other molecular diagnostic programs in cancer and various other indications. In 2016, Rosetta was primarily focused on the commercial launch of its Reveal assay for the classification of indeterminate thyroid nodules, and it signed an exclusive distribution agreement with Rhenium Ltd. for the sales and marketing of Reveal in Israel. In a December earnings release, Rosetta Genomics said it expects FY2017 RosettaGX Reveal revenue to be between $4 million and $5 million. The company is also advancing a number of other…

Continue Reading

WednesdayJan 18, 2017 1:25 pm

NetworkNewsBreaks – aTyr’s (NASDAQ: LIFE) Resolaris™ Obtains Fast Track Designation from FDA, Partial Clinical Hold Removed

Shares of aTyr Pharma (NASDAQ: LIFE) climbed more than 25% in mid-day trade following news that the company’s Resolaris™ candidate was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy 2B, making it the first known therapeutic candidate to receive the designation for this treatment. The FDA also removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials, providing dosing flexibility moving forward. "This Fast Track designation, which is granted to drug candidates addressing serious conditions and that demonstrate the potential to address unmet medical…

Continue Reading

TuesdayJan 17, 2017 3:50 pm

NetworkNewsBreaks – Veru Healthcare (NASDAQ: FHCO) Continues Rally on Launch of OTC Premature Ejaculation Product

Shares of Veru Healthcare (NASDAQ: FHCO) are higher in Monday trade, moving on momentum from the recent launch of the company's proprietary, over-the-counter PREBOOST® product to help prevent premature ejaculation (PE). As the only individually packaged medicated wipe that contains a desensitizing agent (4% benzocaine), PREBOOST allows for discrete, direct and precise dosage with each use. Top line results from an independent clinical study of PREBOOST show that men treated with PREBOOST had statistically significant improvement in their ability to control ejaculation, while 80% were no longer considered to have PE. The intended reach of PREBOOST is two-fold. On one…

Continue Reading

TuesdayJan 17, 2017 1:18 pm

NetworkNewsBreaks – Benitec (NASDAQ: BNTC) Shares Surge on Orphan Drug Designation for BB-301 in the EU

Benitec Biopharma (NASDAQ: BNTC; BNTCW) is trading 71% higher on news that the company’s BB-301 for the treatment of patients with oculopharyngeal muscular dystrophy (OPMD) has been granted Orphan Drug Designation by the European Commission. The designation, which provides regulatory and financial incentives including a 10-year period of marketing exclusivity in the EU after product approval and protocol assistance from the European Medicines Agency (EMA) during the product development phase, was based on favorable recommendation from the EMA Committee for Orphan Medicinal Products (COMP). Entry into the clinic with a phase I/II study in OPMD patients is anticipated in 2018,…

Continue Reading